View : 464 Download: 0
Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Title
- Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Authors
- Yoo, Hee-Jeong; Yoon, Ha-Young; Yee, Jeong; Gwak, Hye-Sun
- Ewha Authors
- 곽혜선
- Issue Date
- 2021
- Journal Title
- PHARMACEUTICALS
- ISSN
- 1424-8247
- Citation
- PHARMACEUTICALS vol. 14, no. 11
- Keywords
- mahuang; ephedrine; weight loss; blood pressure; lipid profiles; systematic review; meta-analysis
- Publisher
- MDPI
- Indexed
- SCIE; SCOPUS
- Document Type
- Review
- Abstract
- Ephedrine, the main active ingredient of mahuang, may lead to weight loss; however, it can also induce cardiovascular side effects. As ephedrine use remains controversial, this study aimed to systematically review previous studies on ephedrine-containing products and perform meta-analysis of the existing evidence on weight, blood pressure (BP), heart rate, and lipid change effects of ephedrine-containing products. We searched for placebo-controlled randomized studies in PubMed, Web of Science, and EMBASE until July 2021 using the following search terms: (ephedr* OR mahuang) AND ( "weight loss " OR obes* OR overweight). Mean differences (MDs) and 95% confidence intervals (CIs) were calculated to evaluate the effects of ephedrine-containing products on weight, BP, heart rate, and lipid profiles. A total of 10 articles were included. Compared with the placebo group, the ephedrine-containing product group was associated with greater weight loss, with an MD of -1.97 kg (95% CI: -2.38, -1.57). In the ephedrine-containing product group, the mean heart rate was 5.76 beats/min higher than in the placebo group (95% CI: 3.42, 8.10), whereas intergroup differences in systolic and diastolic BP were not statistically significant. The ephedrine-containing product group had a significantly higher mean high-density lipoprotein cholesterol level (MD: 2.74 mg/dL; 95% CI: 0.94, 4.55), lower mean low-density lipoprotein cholesterol level (MD: -5.98 mg/dL; 95% CI: -10.97, -0.99), and lower mean triglyceride level (MD: -11.25 mg/dL; 95% CI: -21.83, -0.68) than the placebo group. Compared with placebo, the ephedrine-containing products showed better effects on weight loss and lipid profiles, whereas they caused increased heart rate. The ephedrine-containing products may be beneficial to obese or overweight patients; however, close monitoring is needed, especially heart rate monitoring.
- DOI
- 10.3390/ph14111198
- Appears in Collections:
- 약학대학 > 약학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML